We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
-1.72%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$246M
AUM Growth
-$8.32M
Cap. Flow
+$6.35M
Cap. Flow %
2.58%
Top 10 Hldgs %
46.09%
Holding
106
New
14
Increased
20
Reduced
56
Closed
9

Top Buys

Rank Stock Value
1
CTNM
Contineum Therapeutics
CTNM
+$12.9M
2
CVS icon
CVS Health
CVS
+$2.44M
3
BNTX icon
BioNTech
BNTX
+$2.17M
4
EVH icon
Evolent Health
EVH
+$2.15M
5
SYK icon
Stryker
SYK
+$2.12M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$2.67M
2
PODD icon
Insulet
PODD
+$1.94M
3
EYPT icon
EyePoint Inc
EYPT
+$1.91M
4
ATEC icon
Alphatec Holdings
ATEC
+$1.88M
5
LLY icon
Eli Lilly
LLY
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
51
Olema Pharmaceuticals
OLMA
$1.03B
$1.28M 0.52%
118,480
-21,500
-15% -$233K
BMY icon
52
Bristol-Myers Squibb
BMY
$132B
$1.25M 0.51%
+30,000
New +$1.34M
RCUS icon
53
Arcus Biosciences
RCUS
$3.55B
$1.19M 0.49%
78,385
-15,250
-16% -$246K
CI icon
54
Cigna
CI
$76.1B
$1.16M 0.47%
+3,500
New +$1.21M
MLTX icon
55
MoonLake Immunotherapeutics
MLTX
$1.62B
$942K 0.38%
21,428
-24,867
-54% -$1.05M
BDX icon
56
Becton Dickinson
BDX
$45.6B
$935K 0.38%
+4,000
New +$942K
ARVN icon
57
Arvinas
ARVN
$536M
$927K 0.38%
34,830
-13,950
-29% -$444K
COGT icon
58
Cogent Biosciences
COGT
$7.07B
$722K 0.29%
85,600
-178,100
-68% -$1.35M
ADCT icon
59
ADC Therapeutics
ADCT
$141M
$721K 0.29%
+228,102
New +$907K
INSM icon
60
Insmed
INSM
$22B
$658K 0.27%
9,821
-6,600
-40% -$256K
ILMN icon
61
Illumina
ILMN
$31B
$606K 0.25%
5,810
-646
-10% -$72.5K
UTHR icon
62
United Therapeutics
UTHR
$26.2B
$580K 0.24%
1,820
-775
-30% -$205K
NBIX icon
63
Neurocrine Biosciences
NBIX
$18.7B
$542K 0.22%
3,935
-260
-6% -$35.7K
INCY icon
64
Incyte
INCY
$24.9B
$540K 0.22%
8,905
-500
-5% -$28.3K
GPCR icon
65
Structure Therapeutics
GPCR
$3.52B
$525K 0.21%
13,365
+7,401
+124% +$304K
ROIV icon
66
Roivant Sciences
ROIV
$24.8B
$486K 0.2%
45,957
-3,500
-7% -$38.4K
IONS icon
67
Ionis Pharmaceuticals
IONS
$8.81B
$460K 0.19%
9,660
-440
-4% -$18K
MEDP icon
68
Medpace
MEDP
$16.1B
$456K 0.19%
1,106
-185
-14% -$73.3K
ITCI
69
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$447K 0.18%
6,530
-550
-8% -$38.1K
RPRX icon
70
Royalty Pharma
RPRX
$26.2B
$439K 0.18%
16,650
-2,770
-14% -$76.8K
BPMC
71
DELISTED
Blueprint Medicines
BPMC
$415K 0.17%
3,850
-560
-13% -$56.1K
ALKS icon
72
Alkermes
ALKS
$8.39B
$403K 0.16%
16,730
+2,500
+18% +$61.3K
APLS
73
DELISTED
Apellis Pharmaceuticals
APLS
$401K 0.16%
10,460
+790
+8% +$35.8K
BBIO icon
74
BridgeBio Pharma
BBIO
$16.1B
$394K 0.16%
15,535
-570
-4% -$15.6K
ASND icon
75
Ascendis Pharma A/S
ASND
$16.5B
$364K 0.15%
2,666
-1,345
-34% -$183K
1 2
3
4 5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sectoral Asset Management held 106 positions worth $246M, down 3.3% from $254M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sectoral Asset Management's Q2 2024 filing shows 14 new, 20 increased, 56 reduced and 9 closed positions. Its largest new stake was Contineum Therapeutics: 800,887 shares worth $14.1M. The largest sale was Centene, an estimated $2.67M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sectoral Asset Management's largest Q2 2024 buy was Contineum Therapeutics: 800,887 shares worth $14.1M.
  • Sectoral Asset Management added most to BioNTech in Q2 2024, an estimated $2.17M increase.
  • Sectoral Asset Management's biggest Q2 2024 reduction was Insulet, cutting an estimated $1.94M.
  • Sectoral Asset Management fully exited Centene in Q2 2024, selling an estimated $2.67M.
  • Sectoral Asset Management's ten largest holdings make up 46% of its $246M portfolio in Q2 2024.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q2 2024.
  • Sectoral Asset Management's portfolio value fell 3.3% quarter-over-quarter to $246M.

Based on Sectoral Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.